22 June 2017 | News
Leo Pharma has exclusive rights to license the technology in dermatological indications through an option agreement.
Leo Pharma announced an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin.
The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an autoimmune disease leading to hair loss from all or some parts of the body, usually the scalp.
Under the agreement, Leo Pharma will make an investment that enables validation of the technology in a clinical study in alopecia patients. Leo Pharma has exclusive rights to license the technology in dermatological indications through an option agreement.
The agreement demonstrates Leo Pharma’s ongoing commitment to driving innovation through partnering, acquisitions and investments. Leo Pharma has an open and agile approach to business development, supported by internal R&D and a network of dedicated innovation units. Leo Pharma actively seeks partnering and investment opportunities with the potential to improve dermatology care, including in rare skin diseases. This is the first Leo Pharma R&D agreement to be sourced from the Leo Science & Tech Hub in Boston.